Large Particle Flow Cytometry
Volumetric sample delivery rates 100x faster than a typical flow cytometer and analysis rates that are 10x to 100x faster depending on particle size.
Analyzes sample volumes from microliters to liters and particle sizes from microns to millimeters with return of undiluted, intact sample for further analysis.
Simplifies and shortens workflow by eliminating washing, lysing, and enrichment steps, while simultaneously providing gentle processing that preserves sample physiology and viability so you can get more from your samples.
Pharm Tech chose BennuBio to feature as the cover story for its annual Drug Discovery and Development edition.
“Enter BennuBio This is where BennuBio, a developer of bioanalytical instruments based in New Mexico, could prove to be a game-changer in the area of cellular analysis and vaccine development. BennuBio’s instrument is the Velocyt™, an acoustically focused multi-stream flow cytometer based on multiple patents. The Velocyt™ performs rare cell analysis, rapid analysis of blood cells, and can process large volume samples as well as perform re-analysis of a sample.”
In response to continuing success of their novel large particle flow cytometer, BennuBio has moved to a larger facility to consolidate engineering, administrative and laboratory in one building. Formerly located in the WESST Enterprise Center, and with shared laboratory space at TriCore Reference Laboratories, BennuBio is now located at 6610 Gulton Ct. NE in Albuquerque. CEO, Steven Graves...
BennuBio has hired Matthew Hess as Chief Operations Officer. He has over 20 years experience helping start-up companies bring technology to market. With a background in software engineering and experience in life sciences tools and flow cytometry, he was instrumental in the success of Intellicyt, a local company, which pioneered the concept of high-throughput flow cytometry. After over a decade...
Medical device startup BennuBio Inc. won a $1 million National Institutes of Health grant to add rapid analysis capability for complex, three-dimensional cellular “spheroids” to its existing cell-screening technology.